Monitoring adverse reactions to drugs.
作者信息
Dollery C T, Rawlins M D
出版信息
Br Med J. 1977 Jan 8;1(6053):96-7. doi: 10.1136/bmj.1.6053.96.
Abstract
摘要
相似文献
1
Monitoring adverse reactions to drugs.
Br Med J. 1977 Jan 8;1(6053):96-7. doi: 10.1136/bmj.1.6053.96.
2
New strategies for drug monitoring.
Br Med J. 1977 Apr 2;1(6065):861-2.
3
Post-marketing surveillance of adverse reactions to new medicines.
Br Med J. 1977 Oct 15;2(6093):1001-3. doi: 10.1136/bmj.2.6093.1001.
4
A prescription for monitoring drugs.
Science. 1980 Feb 22;207(4433):853-5. doi: 10.1126/science.7355265.
5
Monitoring of drugs after marketing.
J R Coll Gen Pract. 1983 Jul;33(252):438-41.
6
Identification of adverse reactions to new drugs. III: Alerting processes and early warning systems.
Br Med J (Clin Res Ed). 1983 Feb 5;286(6363):458-60. doi: 10.1136/bmj.286.6363.458.
7
Monitoring the adverse reactions to drugs and the discipline of therapeutic auditing.
Q J Med. 1971 Oct;40(160):570-1.
8
Evaluation of spontaneous reports of adverse reactions to drugs.
Br Med J. 1972 Sep 23;3(5829):746-9. doi: 10.1136/bmj.3.5829.746.
9
Monitoring adverse reactions to new drugs: "restricted release" or "monitored release"?
Br Med J. 1977 Mar 12;1(6062):691-2. doi: 10.1136/bmj.1.6062.691.
10
A consideration of the guidelines for investigating potential new drugs in humans in the United Kingdom.
Methods Find Exp Clin Pharmacol. 1979 Apr;1(1):45-50.
引用本文的文献
1
Pharmacovigilance in perspective.
Drug Saf. 1999 Dec;21(6):429-47. doi: 10.2165/00002018-199921060-00001.
2
European postmarketing surveillance of ramipril in hypertension. 1. Feasibility and study cohort.
Eur J Clin Pharmacol. 1995;49(1-2):73-9. doi: 10.1007/BF00192362.
3
Prospective monitoring for adverse reactions to drugs in general practice.
Br Med J (Clin Res Ed). 1981 Nov 14;283(6302):1305-7. doi: 10.1136/bmj.283.6302.1305.
4
Postmarketing surveillance of adverse drug reactions in general practice. I: search for new methods.
Br Med J (Clin Res Ed). 1981 Apr 4;282(6270):1131-2. doi: 10.1136/bmj.282.6270.1131.
5
Costs of safe medicine.
J R Coll Physicians Lond. 1980 Jul;14(3):153-6.
6
Clinical pharmacology. Drug monitoring.
Br Med J (Clin Res Ed). 1981 Feb 21;282(6264):632-4. doi: 10.1136/bmj.282.6264.632.
7
Cohort study of oestrogen treatment and the risk of endometrial cancer: evaluation of method and its applicability.
Eur J Clin Pharmacol. 1983;25(5):625-32. doi: 10.1007/BF00542350.
8
Identification of adverse reactions to new drugs. I: What have been the important adverse reactions since thalidomide?
Br Med J (Clin Res Ed). 1983 Jan 15;286(6360):199-202. doi: 10.1136/bmj.286.6360.199.
9
Post-marketing surveillance or drug acceptability study?
Br J Clin Pharmacol. 1987 Sep;24(3):281-2. doi: 10.1111/j.1365-2125.1987.tb03170.x.
10
Post-marketing surveillance in the UK (1984).
Br J Clin Pharmacol. 1986;22 Suppl 1(Suppl 1):71S-75S. doi: 10.1111/j.1365-2125.1986.tb02986.x.
Zotero 插件